Association between obesity, high-sensitivity C-reactive protein ≥2 mg/L, and subclinical atherosclerosis: Implications of JUPITER from the multi-ethnic study of atherosclerosis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 6, 2011, Pages 1430-1438

  Blaha, Michael J ^a,c   Rivera, Juan J ^a,b   Budoff, Matthew J ^h   Blankstein, Ron ^d   Agatston, Arthur ^b   O'Leary, Daniel H ^e   Cushman, Mary ^f   Lakoski, Susan ^g   Criqui, Michael H ^h,i   Szklo, Moyses ^j,k   Blumenthal, Roger S ^a   Nasir, Khurram ^a,j  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e ST ELIZABETH'S MEDICAL CENTER   (United States)

^f UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h Department of Family and Preventive Medicine ^*

ⁱ UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^j JOHNS HOPKINS UNIVERSITY   (United States)

^k YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

coronary artery disease; electron beam computed tomography; epidemiology; obesity; vascular biology

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; CALCIUM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BODY MASS; BODY WEIGHT; CAROTID ARTERY; CONTROLLED STUDY; CORONARY ARTERY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTICENTER STUDY; OBESITY; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SUBCLINICAL ATHEROSCLEROSIS;

ADULT; AGED; ATHEROSCLEROSIS; BODY MASS INDEX; C-REACTIVE PROTEIN; CALCIUM; CARDIOVASCULAR DISEASES; CAROTID ARTERIES; CLINICAL TRIALS AS TOPIC; CROSS-SECTIONAL STUDIES; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PYRIMIDINES; SULFONAMIDES; TUNICA INTIMA; TUNICA MEDIA; WAIST CIRCUMFERENCE;

EID: 79957456975     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.111.223768     Document Type: Article

References (38)

1. Brooks GC, Blaha MJ, Blumenthal RS. Relation of C-reactive protein to abdominal adiposity. Am J Cardiol. 2010;106:56-61.
2. Festa A, D'Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102: 42-47. (Pubitemid 30430551)
3. Musunuru K, Kral BG, Blumenthal RS, Fuster V, Campbell CY, Gluckman TJ, Lange RA, Topol EJ, Willerson JT, Desai MY, Davidson MH, Mora S. The use of high-sensitivity assays for C-reactive protein in clinical practice. Nat Clin Pract Cardiovasc Med. 2008;5:621-635.
4. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
5. Yang EY, Nambi V, Tang Z, Virani SS, Boerwinkle E, Hoogeveen RC, Astor BC, Mosley TH, Coresh J, Chambless L, Ballantyne CM. Clinical implications of JUPITER (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) in a U.S. population: insights from the ARIC (Atherosclerosis Risk in Communities) Study. J Am Coll Cardiol. 2009;54:2388-2395.
6. Cushman M, McClure LA, Lakoski SG, Jenny NS. Eligibility for statin therapy by the JUPITER trial criteria and subsequent mortality. Am J Cardiol. 2010;105:77-81.
7. Mora S, Ridker PM. Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER): can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol. 2006;97:33A-41A. (Pubitemid 43139718)
8. Danesh J, Pepys MB. C-reactive protein and coronary disease: is there a causal link? Circulation. 2009;120:2036-2039.
9. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. 2008;359:1897-1908.
10. Elliott P, Chambers JC, Zhang W, Clarke R, Hopewell JC, Peden JF, Erdmann J, Braund P, Engert JC, Bennett D, Coin L, Ashby D, Tzoulaki I, Brown IJ, Mt-Isa S, McCarthy MI, Peltonen L, Freimer NB, Farrall M, Ruokonen A, Hamsten A, Lim N, Froguel P, Waterworth DM, Vollenweider P, Waeber G, Jarvelin MR, Mooser V, Scott J, Hall AS, Schunkert H, Anand SS, Collins R, Samani NJ, Watkins H, Kooner JS. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA. 2009;302:37-48.
11. Reilly MP, Wolfe ML, Localio AR, Rader DJ. Study of Inherited Risk of Coronary Atherosclerosis: C-reactive protein and coronary artery calcification: the Study of Inherited Risk of Coronary Atherosclerosis (SIRCA). Arterioscler Thromb Vasc Biol. 2003;23:1851-1856. (Pubitemid 37254874)
12. Khera A, de Lemos JA, Peshock RM, Lo HS, Stanek HG, Murphy SA, Wians FH Jr, Grundy SM, McGuire DK. Relationship between C-reactive protein and subclinical atherosclerosis: the Dallas Heart Study. Circulation. 2006;113:38-43. (Pubitemid 43958486)
13. Jenny NS, Brown ER, Detrano R, Folsom AR, Saad MF, Shea S, Szklo M, Herrington DM, Jacobs DR Jr. Associations of inflammatory markers with coronary artery calcification: results from the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2010;209:226-229.
14. Hamirani YS, Pandey S, Rivera JJ, Ndumele C, Budoff MJ, Blumenthal RS, Nasir K. Markers of inflammation and coronary artery calcification: a systematic review. Atherosclerosis. 2008;201:1-7.
15. See R, Abdullah SM, McGuire DK, Khera A, Patel MJ, Lindsey JB, Grundy SM, de Lemos JA. The association of differing measures of overweight and obesity with prevalent atherosclerosis: the Dallas Heart Study. J Am Coll Cardiol. 2007;50:752-759. (Pubitemid 47239312)
16. Burke GL, Bertoni AG, Shea S, Tracy R, Watson KE, Blumenthal RS, Chung H, Carnethon MR. The impact of obesity on cardiovascular disease risk factors and subclinical vascular disease: the Multi-Ethnic Study of Atherosclerosis. Arch Intern Med. 2008;168:928-935. (Pubitemid 351679632)
17. Nasir K, Campbell CY, Santos RD, Roguin A, Braunstein JB, Carvalho JA, Blumenthal RS. The association of subclinical coronary atherosclerosis with abdominal and total obesity in asymptomatic men. Prev Cardiol. 2005;8(3):143-8.
18. Cassidy AE, Bielak LF, Zhou Y, Sheedy PF II, Turner ST, Breen JF, Araoz PA, Kullo IJ, Lin X, Peyser PA. Progression of subclinical coronary atherosclerosis: does obesity make a difference? Circulation. 2005;111:1877-1882.
19. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, Greenland P, Jacob DR Jr, Kronmal R, Liu K, Nelson JC, O'Leary D, Saad MF, Shea S, Szklo M, Tracy RP. Multi-Ethnic Study of Atherosclerosis: objectives and design. Am J Epidemiol. 2002;156:871-881. (Pubitemid 35215769)
20. Carr JJ, Nelson JC, Wong ND, McNitt-Gray M, Arad Y, Jacobs DR Jr, Sidney S, Bild DE, Williams OD, Detrano RC. Calcified coronary artery plaque measurement with cardiac ct in population-based studies: standardized protocol of Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary Artery Risk Development in Young Adults (CARDIA) study. Radiology. 2005;234:35-43. (Pubitemid 39658367)
21. Naghavi M, Falk E, Hecht HS, Jamieson MJ, Kaul S, Berman D, Fayad Z, Budoff MJ, Rumberger J, Naqvi TZ, Shaw LJ, Faergeman O, Cohn J, Bahr R, Koenig W, Demirovic J, Arking D, Herrera VL, Badimon J, Goldstein JA, Rudy Y, Airaksinen J, Schwartz RS, Riley WA, Mendes RA, Douglas P, Shah PK. SHAPE Task Force. From vulnerable plaque to vulnerable patient: part III: executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report. Am J Cardiol. 2006;98:2H-15H.
22. Rocha VZ, Lippy P. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol. 2009;6:399-409.
23. Libby P, Ridker PM, Hansson GK. Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54:2129-2138.
24. Cushman M, McClure LA, Howard VJ, Jenny NS, Lakoski SG, Howard G. Implications of increased C-reactive protein for cardiovascular risk stratification in black and white men and women in the US. Clin Chem. 2009;55:1627-1636.
25. Blaha MJ, Bansal S, Rouf R, Golden SH, Blumenthal RS, Defilippis AP. A practical "ABCDE" approach to the metabolic syndrome. Mayo Clin Proc. 2008;83:932-941.
26. Qasim A, Mehta NN, Tadesse MG, Wolfe ML, Rhodes T, Girman C, Reilly MP. Adipokines, insulin resistance, and coronary artery calcification. J Am Coll Cardiol. 2008;52:231-236. (Pubitemid 351915780)
27. Rana JS, Arsenault BJ, Després JP, Côté M, Talmud PJ, Ninio E, Wouter Jukema J, Wareham NJ, Kastelein JJ, Khaw KT, Matthijs Boekholdt S. Inflammatory biomarkers, physical activity, waist circumference, and risk of future coronary heart disease in healthy men and women. Eur Heart J. 2011;32:336-344.
28. Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375:132-140.
29. Boekholdt SM, Kastelein JJ. C-reactive protein and cardiovascular risk: more fuel to the fire. Lancet. 2010;375:95-96.
30. Zhang YX, Cliff WJ, Schoefl GI, Higgins G. Coronary C-reactive protein distribution: its relation to development of atherosclerosis. Atherosclerosis. 1999;145:375-379. (Pubitemid 29359147)
31. Clapp BR, Hirschfield GM, Storry C, Gallimore JR, Stidwill RP, Singer M, Deanfield JE, MacAllister RJ, Pepys MB, Vallance P, Hingorani AD. Inflammation and endothelial function: direct vascular effects of human C-reactive protein on nitric oxide bioavailability. Circulation. 2005;111: 1530-1536. (Pubitemid 40470649)
32. Koike T, Kitajima S, Yu Y, Nishijima K, Zhang J, Ozaki Y, Morimoto M, Watanabe T, Bhakdi S, Asada Y, Chen YE, Fan J. Human C-reactive protein does not promote atherosclerosis in transgenic rabbits. Circulation. 2009; 120:2088-2094.
33. Cao JJ, Arnold AM, Manolio TA, Polak JF, Psaty BM, Hirsch CH, Kuller LH, Cushman M. Association of carotid artery intima-media thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality: the Cardiovascular Health Study. Circulation. 2007; 116:32-38. (Pubitemid 47016244)
34. Everett BM, Kurth T, Buring JE, Ridker PM. The relative strength of C-reactive protein and lipid levels as determinants of ischemic stroke compared with coronary heart disease in women. J Am Coll Cardiol. 2006;48:2235-2242. (Pubitemid 44855447)
35. Folsom AR, Kronmal RA, Detrano RC, O'Leary DH, Bild DE, Bluemke DA, Budoff MJ, Liu K, Shea S, Szklo M, Tracy RP, Watson KE, Burke GL. Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the Multi-Ethnic Study of Atherosclerosis (MESA). Arch Intern Med. 2008;168: 1333-1339. (Pubitemid 351930841)
36. Newman AB, Naydeck BL, Ives DG, Boudreau RM, Sutton-Tyrrell K, O'Leary DH, Kuller LH. Coronary artery calcium, carotid artery wall thickness, and cardiovascular disease outcomes in adults 70 to 99 years old. Am J Cardiol. 2008;101:186-192.
37. Kim HC, Greenland P, Rossouw JE, Manson JE, Cochrane BB, Lasser NL, Limacher MC, Lloyd-Jones DM, Margolis KL, Robinson JG. Multimarker prediction of coronary heart disease risk. J Am Coll Cardiol. 2010;55:2080-2091.
38. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120: 1640-1645.